Dian Diagnostics GroupLtd Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Dian Diagnostics GroupLtd hat ein Gesamteigenkapital von CN¥9.5B und eine Gesamtverschuldung von CN¥3.8B, wodurch sich der Verschuldungsgrad auf 39.9% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen CN¥17.1B bzw. CN¥7.6B. Dian Diagnostics GroupLtd Das EBIT des Unternehmens beträgt CN¥406.9M, so dass der Zinsdeckungsgrad 2.4 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von CN¥1.7B.

Wichtige Informationen

39.9%

Verhältnis von Schulden zu Eigenkapital

CN¥3.78b

Verschuldung

Zinsdeckungsgrad	2.4x
Bargeld	CN¥1.73b
Eigenkapital	CN¥9.48b
Gesamtverbindlichkeiten	CN¥7.60b
Gesamtvermögen	CN¥17.08b

Jüngste Berichte zur Finanzlage

Dian Diagnostics GroupLtd (SZSE:300244) Seems To Use Debt Quite Sensibly

May 24

Recent updates

Dian Diagnostics Group Co.,Ltd.'s (SZSE:300244) Shares Bounce 37% But Its Business Still Trails The Industry

Oct 04

Dian Diagnostics Group Co.,Ltd. (SZSE:300244) Looks Inexpensive But Perhaps Not Attractive Enough

Aug 20

Returns On Capital Signal Tricky Times Ahead For Dian Diagnostics GroupLtd (SZSE:300244)

Jul 12

Dian Diagnostics GroupLtd (SZSE:300244) Will Pay A Smaller Dividend Than Last Year

Jun 10

Dian Diagnostics GroupLtd (SZSE:300244) Seems To Use Debt Quite Sensibly

May 24

Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Apr 30

Investors Holding Back On Dian Diagnostics Group Co.,Ltd. (SZSE:300244)

Apr 22

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 300244Die kurzfristigen Aktiva des Unternehmens (CN¥12.8B) übersteigen seine kurzfristigen Passiva (CN¥4.9B).

Langfristige Verbindlichkeiten: 300244Die kurzfristigen Vermögenswerte des Unternehmens (CN¥12.8B) übersteigen seine langfristigen Verbindlichkeiten (CN¥2.7B).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 300244Die Nettoverschuldung im Verhältnis zum Eigenkapital (21.7%) wird als zufriedenstellend angesehen.

Schulden abbauen: 300244 Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 63.2% auf 39.9% zurückgegangen.

Schuldendeckung: 300244Die Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (42.6%).

Zinsdeckung: 300244Die Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (2.4x Deckung) nicht gut gedeckt.

Dian Diagnostics GroupLtd Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Dian Diagnostics GroupLtd (SZSE:300244) Seems To Use Debt Quite Sensibly

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Dian Diagnostics Group Co.,Ltd.'s (SZSE:300244) Shares Bounce 37% But Its Business Still Trails The Industry

Dian Diagnostics Group Co.,Ltd. to Report Q3, 2024 Results on Oct 24, 2024

New minor risk - Share price stability

Dian Diagnostics Group Co.,Ltd. Approves Interim Cash Dividend for the Year 2024, Payable on September 20, 2024

Dian Diagnostics Group Co.,Ltd. Approves Interim Cash Dividend for the Year 2024

Price target decreased by 15% to CN¥13.76

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Dian Diagnostics Group Co.,Ltd. (SZSE:300244) Looks Inexpensive But Perhaps Not Attractive Enough

Returns On Capital Signal Tricky Times Ahead For Dian Diagnostics GroupLtd (SZSE:300244)

Dian Diagnostics Group Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Dian Diagnostics GroupLtd (SZSE:300244) Will Pay A Smaller Dividend Than Last Year

Dividend reduced to CN¥0.06

Dian Diagnostics Group Co.,Ltd. Announces Dividend on share A for the Year 2023, Payable on June 13, 2024

Dian Diagnostics GroupLtd (SZSE:300244) Seems To Use Debt Quite Sensibly

Price target decreased by 7.5% to CN¥25.72

Consensus EPS estimates fall by 43%

Dian Diagnostics Group Co.,Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Investors Holding Back On Dian Diagnostics Group Co.,Ltd. (SZSE:300244)

Dian Diagnostics Group Co.,Ltd., Annual General Meeting, May 20, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.3% to CN¥28.27

Dian Diagnostics Group Co.,Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Dian Diagnostics Group Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Dian Diagnostics Group Co.,Ltd. Announces Executive Appointments

Price target decreased by 9.9% to CN¥31.56

Third quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 20%

Price target decreased by 8.0% to CN¥37.35

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Dian Diagnostics Group Co.,Ltd. Announces Final Cash Dividend for A Shares, Payable on 31 May 2023

Dian Diagnostics Group Co.,Ltd. Approves Cash Dividend for 2022

Price target decreased by 10% to CN¥38.72

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 18%

Consensus EPS estimates fall by 10%, revenue upgraded

Consensus EPS estimates fall by 43%

Dian Diagnostics Group Co.,Ltd. (SZSE:300244) announces an Equity Buyback for CNY 50 million worth of its shares.

Less than half of directors are independent

Consensus revenue estimates increase by 14%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 14%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Dian Diagnostics Group Co.,Ltd. Announces Final Cash Dividend on A Shares for 2021, Payable on 08 June 2022

Less than half of directors are independent

Dian Diagnostics Group Co.,Ltd. Announces Dividend for 2021

Now 20% undervalued

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Dian Diagnostics Group Co.,Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 21% undervalued after recent price drop

Now 23% undervalued after recent price drop

Price target decreased to CN¥48.50

Third quarter 2021 earnings released: EPS CN¥0.81 (vs CN¥0.64 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.63 (vs CN¥0.80 in 2Q 2020)

Investor sentiment improved over the past week

Price target decreased to CN¥52.85

Dian Diagnostics Group Co.,Ltd. Approved Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.55 (vs CN¥0.011 in 1Q 2020)

Consensus EPS estimates increase to CN¥1.82

Full year 2020 earnings released: EPS CN¥1.29 (vs CN¥0.56 in FY 2019)

New 90-day low: CN¥32.92

Dian Diagnostics Group Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 10, 2021

Investor sentiment deteriorated over the past week

New 90-day high: CN¥43.96

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target raised to CN¥53.63

New 90-day low: CN¥36.20

Analysts update estimates

Third quarter earnings released

Dian Diagnostics Group Co.,Ltd. to Report Q3, 2020 Results on Oct 28, 2020